Gapping down
In reaction to disappointing earnings/guidance:
- CLDR -35.8%, HOME -33.8%, KIRK -31.4%, MIK -16%, LZB -5%, REVG -4.9%, MDB -3.9%, ABM -0.8%
Other news:
- TAK -5.5% (provides updates from Phase 3 TOURMALINE-AL1 clinical trial in AL amyloidosis; did not meet the first of two primary endpoints)
- ORTX -3.3% (prices public offering of 9 mln American Depositary Shares for total gross proceeds of approximately $128 mln)
- VRRM -1.7% (prices underwritten public offering of 15 mln shares of its Class A Common Stock by a selling stockholder at a public offering price of $12.50 per share)
- COUP -1.4% (proposes offering of $500 mln aggregate principal amount of convertible senior notes due 2025)
- DSGX -1.4% (prices offering of 6 mln common shares at a price of $35.50 per common share)
- IIIV -1.3% (prices follow-on public offering of 4,491,763 shares of Class A common stock at $22.75 per share)
- BJ -1.2% (launches follow-on public offering of 17.5 mln shares of common stock by selling stockholders)
- F -1.1% (confirms plan to exit the Ford Bridgend Engine Plant in South Wales)
- FRPT -0.9% (announces public offering of 3,294,653 shares of common stock by stockholders; Affiliates of MidOcean Partners intend to offer 3,294,653 shares of the Company's common stock in an underwritten public offering)
- WFC -0.8% (interim CEO may remain in role, according to Reuters)
Analyst comments:
- KTOS -3% (downgraded to Neutral from Buy at Goldman)
- SAVE -1.2% (downgraded to Neutral from Buy at Goldman)